We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Protein's New Role Discovered in Autoimmune Disease

By Biotechdaily staff writers
Posted on 21 Jan 2008
Investigators have identified the previously unknown role of a chemical ‘messenger' leading to autoimmune disorders like rheumatoid arthritis and lupus. More...
The messenger is the naturally occurring chemical interleukin 17 (IL-17), an immunity protein.

Researchers from the University of Alabama at Birmingham (UAB; USA) discovered an unknown role IL-17 plays in autoimmune and inflammatory responses, aside from its commonly known effects within immunity. Future research will focus on IL-17's unwanted actions and preserve its benefits within the immune system.

In the study, UAB scientists blocked messenger signals from the IL-17 protein to the immune system of mice. This disruption significantly reduced the number of white blood cells, namely, disease-causing B cells, gathered in the laboratory mice's spleen. The number of B-cell clusters decreased from 17 %-2% when the IL-17 protein signals were blocked, according to the study researchers. The decrease was a definitive sign that IL-17 plays a major role on shaping B cells' ability to create more and more disease-causing antibodies.

"The effect of IL-17 to slow down B cells, thereby enhancing their interaction with other immune regulatory cells is a new and exciting discovery,” said John D. Mountz, M.D., Ph.D., UAB professor of medicine and senior author on the study. "This is surprising since previously IL-17 was thought to increase, but not decrease, cell motion. Now the effects of IL-17 on B cells can be explored more fully.”

Many types of B cells make up the human immune system, which is regulated to sense and fight infection without attacking normal, healthy tissue. In autoimmune diseases, this regulatory process becomes imbalanced.

"Knowing more about IL-17's ability to regulate unwanted B-cell migration will generate new ideas in the ongoing search for better drug targets in preventing and treating autoimmune disease,” said Hui-Chen Hsu, Ph.D., an assistant professor in the UAB division of clinical immunology and rheumatology and lead author on the study.

The new findings were published in the online December 23, 2007, issue of the journal Nature Immunology.


Related Links:
University of Alabama at Birmingham

Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Nasopharyngeal Applicator
CalgiSwab 5.5" Sterile Mini-tip Calcium Alginate Nasopharyngeal Swab w/Aluminum HDLE
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.